MCID: SML001
MIFTS: 52

Small Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 15 17
Small Cell Carcinoma, Intermediate Cell 12 71
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 71
Carcinoma, Small Cell 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050685
NCIt 49 C4099
SNOMED-CT 67 5958006
UMLS 71 C0149925 C0262584 C0334239

Summaries for Small Cell Carcinoma

Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to ovarian small cell carcinoma and lung combined type small cell carcinoma. An important gene associated with Small Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and Pathways in cancer. The drugs Paclitaxel and Pembrolizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and cervix, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 934)
# Related Disease Score Top Affiliating Genes
1 ovarian small cell carcinoma 35.1 SYP SMARCA4 ENO2
2 lung combined type small cell carcinoma 35.0 SYP NCAM1
3 cervix small cell carcinoma 34.8 SYP ENO2 CHGA
4 gastric small cell carcinoma 34.6 SYP NCAM1 ENO2 CHGA
5 small cell carcinoma of the bladder 34.6 SYP NKX2-1 KRT7 KRT20 ENO2 CHGA
6 laryngeal small cell carcinoma 34.5 SYP NKX2-1 NCAM1 KIT CHGA
7 endometrial small cell carcinoma 34.4 SYP PTPRC NCAM1 KIT ENO2 CHGA
8 gallbladder small cell carcinoma 34.4 SYP NCAM1 KRT7 ENO2 CHGA
9 ureter small cell carcinoma 34.1 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
10 lung large cell carcinoma 32.9 SYP NKX2-1 NCAM1 CHGA
11 small cell cancer of the lung 32.2 TP53 SYP PTPRC PTEN NKX2-1 NCAM1
12 merkel cell carcinoma 32.0 TP53 SYP PTPRC NKX2-1 NCAM1 KRT7
13 prostate cancer 31.4 TP53 TMPRSS2 SYP SMARCA4 PTEN KRAS
14 in situ carcinoma 31.3 TP53 PTEN EGFR
15 lung oat cell carcinoma 31.3 SYP GRP ENO2 CHGA CALCA
16 squamous cell carcinoma 31.2 TP53 PTEN KRT7 KRT19 EGFR
17 rhabdoid tumor predisposition syndrome 1 31.1 TP53 SYP PTPRC
18 thyroid carcinoma 30.9 PTEN NKX2-1 CALCA
19 pulmonary large cell neuroendocrine carcinoma 30.9 SYP NCAM1 CHGA
20 atypical teratoid rhabdoid tumor 30.9 TP53 SYP SMARCA4 CHGA
21 lung cancer 30.9 TP53 SYP SMARCA4 PTPRC PTEN NKX2-1
22 carcinoid tumors, intestinal 30.9 SYP NKX2-1 ENO2 CHGA
23 gallbladder adenocarcinoma 30.9 TP53 KRT20 EGFR
24 transitional cell carcinoma 30.7 TP53 PTEN KRT7 KRT20 KRT19 KLK3
25 endocervical adenocarcinoma 30.7 TP53 KRT7 KRT20
26 adenocarcinoma 30.7 TP53 PTEN NKX2-1 KRT7 KRT20 KRAS
27 cystadenocarcinoma 30.6 TP53 PTPRC KRT7
28 spindle cell carcinoma 30.6 SYP KRT7 KRT19 ENO2 CHGA
29 sertoli-leydig cell tumor 30.6 SYP KRT7 ENO2
30 leiomyosarcoma 30.6 TP53 PTPRC KIT ENO2
31 barrett esophagus 30.6 TP53 KRT7 KRT20 EGFR
32 cystitis 30.6 TP53 KRT7 KRT20 KIT
33 achalasia 30.6 TP53 KIT ENO2
34 large cell neuroendocrine carcinoma 30.5 SYP NKX2-1 NCAM1 KRT7 KRT20 KIT
35 mucinous cystadenocarcinoma 30.5 PTPRC KRT7 KRT20
36 adenoma 30.5 TP53 SYP KRT7 KRT20 KRAS CHGA
37 endodermal sinus tumor 30.5 KRT7 KLK3 KIT CHGA
38 lung disease 30.5 TP53 NKX2-1 KRT19 GRP ENO2 EGFR
39 mesothelioma, malignant 30.4 NKX2-1 KRT7 KRT20 KRT19
40 constipation 30.4 KIT GRP CHGA CALCA
41 granular cell tumor 30.4 SYP NKX2-1 ENO2
42 papillary transitional carcinoma 30.4 TP53 KRT7 KRT20
43 papillary adenocarcinoma 30.4 TP53 NKX2-1 KRT7 KRT19 KRAS
44 nodular prostate 30.4 SYP KLK3 ENO2
45 ovarian mucinous neoplasm 30.4 KRT7 KRT20 KRAS
46 malignant peripheral nerve sheath tumor 30.4 TP53 KRT7 KIT EGFR
47 neuroendocrine tumor 30.4 SYP NKX2-1 NCAM1 KRT20 KRT19 GRP
48 meningioma, familial 30.4 TP53 SYP PTEN ENO2 EGFR
49 gastrinoma 30.4 SYP GRP CHGA
50 endometrial adenocarcinoma 30.3 TP53 PTEN KRT7 KRAS EGFR

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.07 KIT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.07 PTPRC
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.07 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.07 KRAS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.07 MYCN
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.07 KRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.07 KIT KRAS PTPRC
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.07 KRAS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.07 KRAS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.07 KIT
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.07 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.07 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.07 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.07 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.07 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.07 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-41 10.07 PTPRC
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.07 KIT
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.07 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.07 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.07 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.07 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.07 PTPRC
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.07 KRAS
25 Reduced mammosphere formation GR00396-S 9.17 CHGA EGFR KRAS KRT7 NCAM1 PTEN

MGI Mouse Phenotypes related to Small Cell Carcinoma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 CHGA EGFR GRP KIT KLK3 KRAS
2 cellular MP:0005384 10.39 EGFR ENO2 KIT KRAS KRT19 KRT7
3 growth/size/body region MP:0005378 10.34 CHGA EGFR ENO2 KIT KRAS KRT19
4 nervous system MP:0003631 10.31 CHGA EGFR ENO2 GRP KIT KRAS
5 endocrine/exocrine gland MP:0005379 10.28 CHGA EGFR KIT KRAS KRT19 NKX2-1
6 digestive/alimentary MP:0005381 10.26 EGFR KIT KRAS KRT19 MYCN NKX2-1
7 embryo MP:0005380 10.2 EGFR KIT KRAS KRT19 MYCN PTEN
8 craniofacial MP:0005382 10.17 EGFR ENO2 KIT KRAS KRT19 MYCN
9 neoplasm MP:0002006 10.16 EGFR KIT KRAS KRT19 NKX2-1 PTEN
10 liver/biliary system MP:0005370 10.15 EGFR KIT KRAS KRT19 MYCN PTEN
11 normal MP:0002873 10.15 EGFR KIT KRAS KRT19 MYCN NKX2-1
12 muscle MP:0005369 10.13 CHGA EGFR KIT KLK3 KRAS MYCN
13 no phenotypic analysis MP:0003012 10.06 CHGA EGFR KIT KRAS KRT19 MYCN
14 limbs/digits/tail MP:0005371 10.05 EGFR KIT KRAS MYCN PTEN SMARCA4
15 renal/urinary system MP:0005367 9.96 CHGA EGFR KIT KRAS KRT7 MYCN
16 reproductive system MP:0005389 9.85 CHGA EGFR KIT KRAS KRT19 MYCN
17 pigmentation MP:0001186 9.8 EGFR KIT KRAS PTEN SMARCA4 TP53
18 respiratory system MP:0005388 9.77 EGFR ENO2 GRP KIT KRAS KRT19
19 skeleton MP:0005390 9.32 EGFR KIT KRAS KRT19 MYCN NKX2-1

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Pembrolizumab Approved Phase 3 1374853-91-4
3
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
5
Etoposide Approved Phase 3 33419-42-0 36462
6
leucovorin Approved Phase 3 58-05-9 6006 143
7
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
8
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
9
Gemcitabine Approved Phase 3 95058-81-4 60750
10
nivolumab Approved Phase 3 946414-94-4
11
Durvalumab Approved, Investigational Phase 3 1428935-60-7
12
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
15
Osimertinib Approved Phase 3 1421373-65-0 71496458
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
18
Camptothecin Experimental Phase 3 7689-03-4
19 Amrubicin Investigational Phase 3 110267-81-7
20
Tremelimumab Investigational Phase 3 745013-59-6
21 Albumin-Bound Paclitaxel Phase 3
22 Tubulin Modulators Phase 3
23 Antimitotic Agents Phase 3
24 Dermatologic Agents Phase 3
25 Podophyllotoxin Phase 3 518-28-5
26 Keratolytic Agents Phase 3
27 Pharmaceutical Solutions Phase 3
28 Etoposide phosphate Phase 3
29 Immunologic Factors Phase 3
30 Anti-Infective Agents Phase 3
31 Folic Acid Antagonists Phase 3
32 Vitamin B Complex Phase 3
33 Antiviral Agents Phase 3
34 Immunosuppressive Agents Phase 3
35 Folate Phase 3
36 Antimetabolites Phase 3
37 Vitamin B9 Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Immunoglobulins Phase 3
40 Antibodies Phase 3
41 Antibodies, Monoclonal Phase 3
42 Immunoglobulins, Intravenous Phase 3
43 Immunoglobulin G Phase 3
44 Angiogenesis Inhibitors Phase 3
45
Apatinib Phase 3 811803-05-1
46 Endothelial Growth Factors Phase 3
47
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
48 Mitogens Phase 3
49 Hematinics Phase 3
50 Epoetin alfa Phase 3 113427-24-0

Interventional clinical trials:

(show top 50) (show all 270)
# Name Status NCT ID Phase Drugs
1 A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
2 Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer Unknown status NCT02688036 Phase 3
3 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
4 Randomized Study Comparing Two Strategies Carboplatin and Etoposide Topotecan in Patients With SCLC on the Second Row With Relapsed at Least Three Months After Initial Response to Chemotherapy With Platinum-etoposide 6 Cycles Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
5 The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
6 Randomized, Phase III Trial Comparing Etoposide/Cisplatin (EP) With Irinotecan/Cisplatin (IP) in Patients With Previously Untreated, Extensive Disease (ED) Small Cell Lung Cancer (SCLC) Completed NCT00349492 Phase 3 IP
7 A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE) Completed NCT03061812 Phase 3 Rovalpituzumab tesirine;Topotecan
8 A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
9 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
10 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
11 AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
12 A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
13 MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Recruiting NCT04155034 Phase 3
14 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Recruiting NCT03811002 Phase 2, Phase 3 Atezolizumab;Carboplatin;Cisplatin;Etoposide
15 Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer Recruiting NCT04192682 Phase 2, Phase 3 Anlotinib Hydrochloride
16 A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Recruiting NCT03703297 Phase 3 Durvalumab;Tremelimumab
17 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC Recruiting NCT04214262 Phase 3 Atezolizumab
18 Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer Recruiting NCT02635009 Phase 2, Phase 3
19 Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Recruiting NCT04092283 Phase 3 Carboplatin;Cisplatin;Etoposide;Paclitaxel;Pemetrexed Disodium
20 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
21 Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO Recruiting NCT04267848 Phase 3 Carboplatin;Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed Disodium
22 PARAT PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study Recruiting NCT03632603 Phase 3
23 A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Active, not recruiting NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
24 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Active, not recruiting NCT02595944 Phase 3
25 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00324805 Phase 3 Cisplatin;Docetaxel;Gemcitabine Hydrochloride;Pemetrexed Disodium;Vinorelbine Tartrate
26 A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN) Active, not recruiting NCT03043872 Phase 3 Durvalumab;Tremelimumab;Carboplatin;Cisplatin;Etoposide
27 Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Not yet recruiting NCT04402788 Phase 2, Phase 3 Atezolizumab
28 A Randomized Controlled Study of Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy Not yet recruiting NCT02875457 Phase 3 apatinib;etoposide and cisplatin;placebo;etoposide and cisplatin
29 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting NCT04181060 Phase 3 Osimertinib
30 Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Suspended NCT02193282 Phase 3 Erlotinib Hydrochloride
31 Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) Terminated NCT00310232 Phase 3 Epoetin Alfa
32 A Randomized, Phase III Dose Response Study of Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Lung Withdrawn NCT00006344 Phase 3
33 The Effect Of Aspirin On Survival Following Potentially Curative Resection Of Non Small Cell Carcinoma Of The Lung The Big A Trial Withdrawn NCT01058902 Phase 3 Aspirin 75 mg
34 Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer Unknown status NCT01635400 Phase 2 Irinotecan
35 Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer Unknown status NCT01900951 Phase 2 Temozolomide
36 Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma Unknown status NCT01574729 Phase 2 Surgery combined with rAd-p53 gene therapy
37 Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Nab-paclitaxel as a Single Agent in the Small Cell Lung Cancer Patients With Extensive Disease and Failed to First Line/ Second Line Chemotherapy Unknown status NCT02262897 Phase 2 Nab-paclitaxel
38 Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma Unknown status NCT00625352 Phase 2 Gemcitabine, UFT
39 Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer Unknown status NCT01592422 Phase 2
40 Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2 Unknown status NCT00906061 Phase 2 Gemcitabine and Docetaxel
41 A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer Unknown status NCT01417806 Phase 2 Topotecan and Pasireotide
42 Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) Unknown status NCT01027676 Phase 1, Phase 2 Study treatment
43 A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB Unknown status NCT01158248 Phase 2 cisplatin
44 Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) Completed NCT00298896 Phase 2 SNS-595
45 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
46 Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer Completed NCT00308529 Phase 2 irinotecan;carboplatin;bevacizumab
47 Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study Completed NCT00453154 Phase 1, Phase 2 Carboplatin;Cisplatin;Etoposide;Sunitinib Malate
48 An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer Completed NCT00412880 Phase 2 BI 2536
49 Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer Completed NCT00191750 Phase 2 Pemetrexed
50 A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00294931 Phase 2 irinotecan;carboplatin;bevacizumab

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

MalaCards organs/tissues related to Small Cell Carcinoma:

40
Lung, Prostate, Cervix, Ovary, Brain, Breast, Bone

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 6790)
# Title Authors PMID Year
1
What Is the Significance of Variant Histology in Urothelial Carcinoma? 61
31530497 2020
2
Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue. 61
32217611 2020
3
Pure abscopal effect of radiotherapy in a salivary gland carcinoma: Case report, literature review, and a search for new approaches. 61
32192840 2020
4
A California Cancer Registry Analysis of Urothelial and Non-urothelial Bladder Cancer Subtypes: Epidemiology, Treatment, and Survival. 61
32144047 2020
5
A rare case of penile metastases from small cell prostate cancer. 61
32576470 2020
6
Gender and lung cancer-SEER-based analysis. 61
32532368 2020
7
Review of diseases and health management in zebrafish Danio rerio (Hamilton 1822) in research facilities. 61
32291793 2020
8
[Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor]. 61
32192753 2020
9
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. 61
32534809 2020
10
Lung nuclear protein in testis carcinoma in an elderly Korean woman: A case report with cytohistological analysis. 61
32319714 2020
11
Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry. 61
32488689 2020
12
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis. 61
32575483 2020
13
Fungating Anal Mass: Extrapulmonary Small Cell Carcinoma Masquerading as a Hemorrhoid. 61
31848872 2020
14
Rare case of metastatic small cell carcinoma of the nasopharynx to the pancreas. 61
32522725 2020
15
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. 61
32514486 2020
16
Patterns of Care and Outcomes for Small Cell Carcinoma of the Cervix: A National Retrospective Analysis of 542 Cases. 61
32529135 2020
17
Successful pregnancy following chemotherapy in a survivor of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): A case report and review of literature. 61
32405521 2020
18
FDG PET/CT in Diagnosing COVID-19 Infection in a Cancer Patient With Exposure History But Minimal Symptoms. 61
32433162 2020
19
[Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia]. 61
32283582 2020
20
Misdiagnosis of Small Cell Prostate Cancer: Lessons Learned. 61
32494549 2020
21
Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 Ovarian Cancer Families: How young is too young? 61
32382648 2020
22
Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type. 61
32409304 2020
23
[Surgical Treatment of Lung Cancer Combined with Interstitial Lung Disease]. 61
32429636 2020
24
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. 61
32521509 2020
25
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice. 61
32399958 2020
26
Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder. 61
31463895 2020
27
SMARCA family of genes. 61
32312722 2020
28
Prognostic value of biomarkers in primary small cell carcinoma of the esophagus. 61
32133785 2020
29
Long-term survival in a stage IV small cell carcinoma of the endometrium. 61
32420439 2020
30
Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis. 61
32162763 2020
31
[Clinicopathological and genetic characteristics of lung cancer in the lungs of explanted from lung transplant recipients]. 61
32392931 2020
32
Thymic Small Cell Carcinoma Associated With Lambert-Eaton Myasthenic Syndrome. 61
31586614 2020
33
A Rare Case of Gallbladder Small Cell Carcinoma. 61
32394121 2020
34
The Russian Radiobiological Human Tissue Repository: characteristics of biological specimens donated by nuclear workers with lung cancer. 61
31976795 2020
35
Relationships and Qualitative Evaluation Between Diffusion-Weighted Imaging and Pathologic Findings of Resected Lung Cancers. 61
32397172 2020
36
Small Cell Carcinoma of Bladder; Still A Diagnostic and Therapeutic Challenge: Seven Years of Experience and Follow-up in A Referral Center. 61
32309874 2020
37
Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report. 61
32477576 2020
38
[The Efficacy of Amrubicin Therapy as a Second Line Treatment in Patients with Small Cell Carcinoma of the Prostate : A Case Report]. 61
32483946 2020
39
Small cell carcinoma of the upper urinary tract and factors associated with progress survival: a systematic review and pooled analysis. 61
30421591 2020
40
Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. 61
32317009 2020
41
[A Case of Biliary Neuroendocrine Tumor with Neo Adjuvant Chemotherapy]. 61
32389986 2020
42
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. 61
31954538 2020
43
[A Case of Esophageal Neuroendocrine Carcinoma(NEC)Treated with Collective Treatment]. 61
32389996 2020
44
[The pathology of hereditary ovarian tumors]. 61
32178889 2020
45
Pulmonary small cell carcinoma: Review, common and uncommon differentials, genomics and management. 61
32348027 2020
46
Extrapulmonary small cell carcinoma: Prognostic factors, patterns of care, and overall survival. 61
32336623 2020
47
Primary small cell carcinoma of the esophagus: progression in the last decade. 61
32395546 2020
48
Recurrent Small Cell Carcinoma of the Lung With Cutaneous Metastasis in Breast. 61
32293691 2020
49
Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human. 61
30787448 2020
50
Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report. 61
32052251 2020

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 PTPRC NCAM1 KRT7 KRT20 KRT19 KRAS
2 12.61 TP53 PTEN KRAS KLK3 KIT EGFR
3
Show member pathways
12.51 TP53 PTEN KRAS KIT EGFR
4
Show member pathways
12.47 TP53 SMARCA4 PTEN KRAS KIT EGFR
5
Show member pathways
12.45 TP53 TMPRSS2 PTEN KRAS KLK3 KIT
6 12.27 SYP NKX2-1 NCAM1 MYCN ENO2 CALCA
7
Show member pathways
12.12 TP53 PTEN KLK3 EGFR
8 11.85 TP53 SMARCA4 PTEN EGFR
9 11.71 TP53 PTEN KRAS EGFR
10 11.64 PTPRC NCAM1 KIT
11 11.62 SYP SMARCA4 NCAM1
12 11.58 PTPRC NCAM1 KIT
13 11.56 TP53 KRAS EGFR
14 11.54 TP53 SMARCA4 PTEN KRAS EGFR
15 11.51 TP53 PTEN MYCN
16 10.87 TP53 PTEN KRAS KIT EGFR

GO Terms for Small Cell Carcinoma

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic side of plasma membrane GO:0009898 8.8 PTPRC PTEN KIT

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.73 TP53 PTPRC NCAM1 KRT7 KRT19 EGFR
2 hematopoietic progenitor cell differentiation GO:0002244 9.63 TP53 PTPRC KIT
3 positive regulation of gene expression GO:0010628 9.63 TP53 PTEN NKX2-1 MYCN KRAS KIT
4 positive regulation of MAP kinase activity GO:0043406 9.58 KRAS KIT EGFR
5 cerebral cortex cell migration GO:0021795 9.48 NKX2-1 EGFR
6 bone marrow development GO:0048539 9.43 TP53 PTPRC
7 mast cell chemotaxis GO:0002551 9.37 KIT CHGA
8 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.32 GRP CHGA
9 mast cell cytokine production GO:0032762 8.96 KIT CHGA
10 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.8 TP53 MYCN EGFR

Sources for Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....